Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 9,000 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
19th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Lymphoid Diseases
- 50 views
- March 11, 2024
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
FEATURING
Aleksandr Lazaryan
- 332 views
- March 11, 2024
- 1
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should Use a Response-Adapted Approach to Transplant
FEATURING
Kenneth Shain
- 232 views
- March 11, 2024
- 1
Moffitt Cancer Center
Newly Diagnosed Myeloma: Why We Should NOT Use a Response-Adapted Approach to Transplant
FEATURING
Omar Castañeda-Puglianini
- 192 views
- March 11, 2024
- 1
Moffitt Cancer Center
Making Sense of the New Classification Systems for MDS in 2024
FEATURING
Rami Komrokji
- 444 views
- March 8, 2024
- 3
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
FEATURING
Hany Elmariah
- 330 views
- March 7, 2024
- 5
Moffitt Cancer Center
Optimal Timing of CAR-T in Myeloma: Case-Based Discussion
FEATURING
Ciara Freeman
- 31 views
- March 7, 2024
Moffitt Cancer Center
2024 Updates on Frontline Treatment of Advanced Stage Hodgkin Lymphoma
FEATURING
Hayder Saeed
- 40 views
- March 6, 2024
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Plasma Cell Dyscrasias
- 117 views
- March 6, 2024
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024
Moffitt Cancer Center
Optimal Management of Patients With CLL in 2024: Interactive Cases Discussion
FEATURING
Javier Pinilla-Ibarz
- 154 views
- March 4, 2024
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
FEATURING
Julio Chavez
- 826 views
- March 4, 2024
- 4
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When?
FEATURING
Ariel Grajales-Cruz
- 267 views
- March 4, 2024
- 6